Mankind Pharma Share Price Target Set at Rs 2,812 as InCred Initiates Add Rating

The Mankind Pharma share price target has been set at Rs 2,812 by InCred, which initiated coverage with an add rating on 7 July 2026. Mankind Pharma was quoting at Rs 2,521.00, down 0.76 percent, after touching an intraday high of Rs 2,579.15 and a low of Rs 2,521.00.

InCred’s initiation cites a structural shift underway at Mankind Pharma, moving from a generics-led business model toward research and development along with specialty therapies, a transition the brokerage views as strategically significant even though it will take time to show up fully in earnings.

Click Here – Get Free Investment Predictions

InCred’s Mankind Pharma Share Price Target Note: Key Points

Observation	Detail
Rating	Add (initiated)
Mankind Pharma Share Price Target	Rs 2,812
Implied Upside vs CMP (Rs 2,521)	~11.5%
Strategic Shift Noted	Generics-led model moving toward R&D and specialty therapies
Key Deal Cited	BSV acquisition strengthens specialty biologics portfolio
Recent Growth Driver	Acquisitions rather than organic volumes
Outlook on Specialty Strategy	Benefits expected to accrue gradually
CMP (7 July 2026)	Rs 2,521.00 (-0.76%)

Why InCred Set This Mankind Pharma Share Price Target

InCred’s Rs 2,812 target reflects a constructive but measured view. The brokerage explicitly notes that Mankind Pharma’s recent growth has been driven more by acquisitions than organic volume expansion, with the BSV acquisition specifically called out as strengthening the company’s specialty biologics portfolio. This is a meaningful strategic pivot for a company historically known for its generics and consumer healthcare brands in the Indian market.

Importantly, InCred frames the benefits from this specialty strategy as an outcome that will accrue gradually rather than immediately, tempering near-term earnings expectations even while the initiation itself carries a constructive add rating.

Get Research-Backed Stock Ideas from a SEBI Registered Investment Advisor

What the Generics-to-Specialty Shift Means for Mankind Pharma

India’s pharmaceutical majors have increasingly looked to R&D-driven specialty therapies and biologics to escape the margin pressure typical of commoditised generics manufacturing. Mankind Pharma’s pivot, anchored by the BSV acquisition, positions the company to participate in this broader industry shift, though InCred’s own note acknowledges that near-term growth is still acquisition-led rather than reflecting organic specialty pipeline traction yet.

What Should Investors Watch Next

Investors tracking this Mankind Pharma share price target should watch for organic volume growth trends in the specialty and biologics segments in upcoming quarterly results, integration progress on the BSV acquisition, and whether other brokerages initiate or revise coverage with similar or differing views on the pace of this strategic transition.

Download the Univest iOS App or Univest Android App to track Mankind Pharma live and get brokerage target updates daily.

Conclusion

InCred has initiated an add rating on Mankind Pharma with a share price target of Rs 2,812, citing the company’s shift from a generics-led model toward R&D and specialty therapies, anchored by the BSV acquisition. The stock traded at Rs 2,521.00 on 7 July 2026, down 0.76 percent. Organic growth in the specialty portfolio over coming quarters is the key thing to watch.

Frequently Asked Questions on the Mankind Pharma Share Price Target

What is InCred’s Mankind Pharma share price target?

Ans. InCred has initiated an add rating on Mankind Pharma with a share price target of Rs 2,812, implying upside of about 11.5 percent from the stock’s current level of around Rs 2,521.

Why did InCred initiate coverage on Mankind Pharma with an add rating?

Ans. InCred’s initiation cites Mankind Pharma’s structural shift from a generics-led model toward R&D and specialty therapies, with the BSV acquisition strengthening its specialty biologics portfolio.

Is Mankind Pharma’s recent growth organic or acquisition-driven?

Ans. According to InCred’s note, Mankind Pharma’s recent growth has been driven more by acquisitions than organic volumes, though the brokerage expects benefits from the specialty strategy to accrue gradually over time.

What is the Mankind Pharma share price today?

Ans. Mankind Pharma was quoting at Rs 2,521.00 on 7 July 2026, down 0.76 percent, after touching an intraday high of Rs 2,579.15 and a low of Rs 2,521.00.

What is the BSV acquisition mentioned in InCred’s note?

Ans. The BSV acquisition is a deal that InCred cites as strengthening Mankind Pharma’s specialty biologics portfolio, forming a key part of the company’s strategic shift away from a purely generics-led business.

Why is a shift from generics to specialty therapies significant for pharma companies?

Ans. Specialty therapies and biologics typically offer better margins and differentiation than commoditised generics, and Indian pharma majors have increasingly pursued this shift to escape pricing pressure in the generics business.

Should investors buy Mankind Pharma based on InCred’s rating?

Ans. This article does not constitute investment advice. Investors should evaluate the pace of organic growth in the specialty portfolio and overall valuations, and consult a SEBI registered financial advisor before investing.